An international research team has deciphered a mechanism of the evolutionary arms race in human cells. The findings provide ...

Actithera A/S is poised to bring small-molecule pharmacokinetics to radiopharmaceuticals after closing a $75.5 million series A that will fund initial clinical development of a candidate targeting the ...

BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), today announced the close of an oversubscribed $75.5 ...

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Cardiac fibroblasts are the primary cell type responsible for deposition of extracellular matrix in the heart, providing support to the contracting myocardium and contributing to a myriad of ...